These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27643774)

  • 1. "Gadolinium-Phobia:" Not a Helpful "Criterion" for Indication for Gadolinium-based Contrast Agent Administration in Multiple Sclerosis.
    Goischke HK
    Radiology; 2016 Oct; 281(1):323-4. PubMed ID: 27643774
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
    Gonzalez-Scarano F; Grossman RI; Galetta S; Atlas SW; Silberberg DH
    Ann Neurol; 1987 Mar; 21(3):300-6. PubMed ID: 3606036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Gadolinium-based Contrast Material Needed for MRI Follow-up of Multiple Sclerosis?
    Saindane AM
    Radiology; 2019 May; 291(2):436-437. PubMed ID: 30860449
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.
    Tourdias T; Roggerone S; Filippi M; Kanagaki M; Rovaris M; Miller DH; Petry KG; Brochet B; Pruvo JP; Radüe EW; Dousset V
    Radiology; 2012 Jul; 264(1):225-33. PubMed ID: 22723563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents.
    Gentili L; Capuano R; Gaetani L; Fiacca A; Bisecco A; d'Ambrosio A; Mancini A; Guercini G; Tedeschi G; Parnetti L; Gallo A; Di Filippo M
    J Neurol Sci; 2022 Nov; 442():120422. PubMed ID: 36162167
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial Comment: Gadolinium-Based Contrast Agent and the Central Vein Sign.
    Rubinstein D
    AJR Am J Roentgenol; 2023 Jan; 220(1):125. PubMed ID: 36069490
    [No Abstract]   [Full Text] [Related]  

  • 7. [Magnetic resonance imaging of disseminated sclerosis].
    Christiansen AP; Wanscher B; Larsson HB; Henriksen O
    Ugeskr Laeger; 1994 Oct; 156(43):6348-52. PubMed ID: 7810007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncovering and characterizing multiple sclerosis lesions: the aid of fluid-attenuated inversion recovery images in the presence of gadolinium contrast agent.
    Bagnato F
    J Neuroimaging; 2009 Jul; 19(3):201-4. PubMed ID: 19187471
    [No Abstract]   [Full Text] [Related]  

  • 9. [Contrast agents in MRI-diagnosis of multiple sclerosis].
    Abakumova TO; Nukolova NV; Gusev EI; Chekhonin VP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):58-65. PubMed ID: 25909791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone.
    Krapf H; Mauch E; Fetzer U; Laufen H; Kornhuber HH
    Neuroradiology; 1995 Feb; 37(2):113-9. PubMed ID: 7760994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging new lesions: enhancing our understanding of multiple sclerosis pathogenesis.
    Fisher E; Reich DS
    Neurology; 2013 Jul; 81(3):202-3. PubMed ID: 23761620
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.
    Raynaud JS; Darmon-Kern E; Lancelot E; Laurent AC; Desché P
    Radiol Med; 2018 Jun; 123(6):432-433. PubMed ID: 29476438
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to: RE: effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain-a retrospective study in 158 multiple sclerosis (MS) patients.
    Splendiani A
    Radiol Med; 2018 Jul; 123(7):535-537. PubMed ID: 29560604
    [No Abstract]   [Full Text] [Related]  

  • 14. Brain MR post-gadolinium contrast in multiple sclerosis: the role of magnetization transfer and image subtraction in detecting more enhancing lesions.
    Gavra MM; Voumvourakis C; Gouliamos AD; Sfagos C; Vlahos LJ
    Neuroradiology; 2004 Mar; 46(3):205-10. PubMed ID: 14985887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do you believe in Gad?
    Maghzi AH; Sicotte NL; Waubant E
    Mult Scler Relat Disord; 2020 Sep; 44():102299. PubMed ID: 32593143
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis.
    Kremer S; Lamy J; Magnus A; Oesterle H; Jeantroux J; Trunet S; Armspach JP; Dietemann JL; de Sèze J
    Neurology; 2013 Jul; 81(3):206-10. PubMed ID: 23761623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine Gadolinium Use for MRI Follow-Up of Multiple Sclerosis: Counterpoint-Gadolinium Should Not Always Be Used to Assess Disease Activity.
    Rovira À; Auger C
    AJR Am J Roentgenol; 2022 Jul; 219(1):26-27. PubMed ID: 34786958
    [No Abstract]   [Full Text] [Related]  

  • 18. Routine Gadolinium Use for MRI Follow-Up of Multiple Sclerosis: Point-The Role of Leptomeningeal Enhancement.
    Okar SV; Reich DS
    AJR Am J Roentgenol; 2022 Jul; 219(1):24-25. PubMed ID: 34786959
    [No Abstract]   [Full Text] [Related]  

  • 19. Contrast enhanced magnetic resonance imaging of the brain using gadolinium-DTPA.
    Valk J; de Slegte RG; Crezee FC; Hazenberg GJ; Thjaha SI; Nauta JJ
    Acta Radiol; 1987; 28(6):659-65. PubMed ID: 2962597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fat-saturated post gadolinium T1 imaging of the brain in multiple sclerosis.
    Al-Saeed O; Ismail M; Athyal R; Sheikh M
    Acta Radiol; 2011 Jun; 52(5):570-4. PubMed ID: 21498296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.